The Patent Finder

Vaccinex, Inc.

41 patents currently held · Updated Nov 17, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

5
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 28, 2027
    The maintenance fee for ANTI-SEMA4D Antibodies and Epitopes (US 9,090,709) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
  • 1 fee due Feb 20, 2027
    The maintenance fee for Use of SEMAPHORIN-4D Binding Molecules for Treating Neurodegenerative Disorders (US 10,385,136) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Jun 3, 2027
    The maintenance fee for Use of Semaphorin-4D Binding Molecules to Promote Neurogenesis Following Stroke (US 10,494,440) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
  • 3 fees due Jul 2 to 26, 2027 · next Jul 2
  • 2 fees due Aug 2 to 4, 2027 · next Aug 2
  • 1 fee due Sep 3, 2027
    The maintenance fee for Integral Membrane Protein Display on Poxvirus Extracellular Enveloped Virions (US 10,577,427) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
  • 3 fees due Nov 5 to 14, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,919,594Human ANTI-CD100 Antibodies
In force
 · High confidence
In forceHigh confidence
US 8,816,058Polynucleotides Encoding Anti-CD100 Antibodies or Antigen-binding Fragments Thereof
In force
 · High confidence
In forceHigh confidence
US 12,006,364ANTI-CD100 Antibodies and Methods for Using the Same
In force
 · High confidence
In forceHigh confidence
US 8,496,938ANTI-CD100 Neutralizing Antibodies and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,676,840Anti-CD100 Neutralizing Antibodies and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,274,149ANTI-CD100 Antibodies and Methods for Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,605,055Anti-CD100 Antibodies and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 8,834,883Anti-VEGF Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,829,550Polynucleotides Encoding ANTI-CXCL13 Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,534,488Use of SEMAPHORIN-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
In force
 · High confidence
In forceHigh confidence
10 of 41 patents shown.
Pro members see all 41.
Pro members: see all 41 patents
Also on record, not counted in the 41: 4 patents in force now held by others · 16 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 6 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited